Dr. Bin Shi currently is a Research Fellow in the In Vivo Pharmacology Department at Merck, and the Principal Investigator (PI) overseeing anti-cancer and infectious disease drug evaluation using animal models to support development of Merck’s compounds in pre-clinical and clinical PhI-III trials.  Bin completed her Thomas Jefferson University in Philadelphia, her Master of Science degree at State University of New York in Syracuse, and her Bachelor of Science degreeatNankai University. Bin has been working in the pharmaceutical industries in the USA for over 16 years. She has been an active member of AACR (American Association of Cancer Research) since 2006 and a member of NSH (National Society of Histotechnology).  Bin has published more than 50 papers, abstracts and patents in reputed journals and conferences, serving as the first and corresponding author in the manuscripts. Bin has been also serving as aninvited reviewer for several peer reviewed journals and an invited speaker at several conferences.  She is also actively involved in working community services, including a leading role for Connectivity of LINK in Merck to leverage internal networking, knowledge and communication.  Bin is a lifetime SAPA member, and serves in the senior leadership team (SLT) with increased responsibility: Executive Council, General Secretary, and VP of Public Affairs, Communication and Outreach of SAPA-GP.


Bin Shi, PhD

Principal Investigator


  • : 215-896-4485

  • DEPARTMENTPharmacology Department